In Reply We appreciate the interest of Davido et al in our 2018 publication1 in JAMA Surgery regarding Clostridium difficile infection (CDI), and we equally appreciate the opportunity provided by the journal to respond to their comments. It is important to note that the impetus for this study rests on in vivo translational work in a murine model of C difficile2,3 by one of our study collaborators (E.L.B.). This previous work demonstrated that microbiota induction of the cytokine IL-25 protected from death from C difficile colitis via eosinophils. The focus of our studies is the host-pathogen interaction. In particular, we are interested in host response to CDI and how that may predict the development of disease-related adverse events.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Kulaylat AS, Buonomo EL, Stewart DB. Interest of Eosinophil Count in Bacterial Infections to Predict Antimicrobial Therapy Efficacy—Reply. JAMA Surg. Published online February 13, 2019154(5):464–465. doi:10.1001/jamasurg.2018.5596
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: